EVALUATING THE USE OF DROTRECOGIN ALFA (ACTIVATED) IN THE TREATMENT OF SEVERE SEPSIS IN FRANCE: OVERVIEW OF A 3-YEAR SURVEY PERIOD

被引：0
|
作者：
Cariou, A. [1 ]
Montravers, P. [2 ]
Guidet, B. [3 ]
Martin, C. D. [4 ]
Fillon, F. [5 ]
Granados, D.
Sapin, H. [5 ]
Tcherny-Lessenot, S. [5 ]
Payen, D. [6 ]
机构：
[1] Cochin Hosp, Med Intens Care Unit, Paris, France
[2] Hop Xavier Bichat, Surg Intens Care Unit, Paris, France
[3] St Antoine Hosp, Med Intens Care Unit, Paris, France
[4] North Hosp, Med Intens Care Unit, Marseille, France
[5] Eli Lilly & Co, Dept Med, Suresnes, France
[6] Univ Paris 07, Lariboisiere Univ Hosp, Med Intens Care Unit, Paris, France
来源：
INTENSIVE CARE MEDICINE | 2010年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
0425
引用
收藏
页码：S192 / S192
页数：1
相关论文
共 50 条
  • [41] Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
    Vincent, Jean-Louis
    O'Brien, James, Jr.
    Wheeler, Arthur
    Wittebole, Xavier
    Garg, Rekha
    Trzaskoma, Benjamin L.
    Sundin, David P.
    [J]. CRITICAL CARE, 2006, 10 (03)
  • [42] The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
    Martin, Greg
    Brunkhorst, Frank M.
    Janes, Jonathan M.
    Reinhart, Konrad
    Sundin, David P.
    Garnett, Kassandra
    Beale, Richard
    [J]. CRITICAL CARE, 2009, 13 (03)
  • [43] The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
    Greg Martin
    Frank M Brunkhorst
    Jonathan M Janes
    Konrad Reinhart
    David P Sundin
    Kassandra Garnett
    Richard Beale
    [J]. Critical Care, 13
  • [44] The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies
    Machala, W
    Wachowicz, N
    Komorowska, A
    Gaszynski, W
    [J]. MEDICAL SCIENCE MONITOR, 2004, 10 (07): : CS31 - CS36
  • [45] Assessement of the additional cost of drotrecogin alfa (activated) relative to standard care in the treatment of severe sepsis in a multicentic observational study in France
    Payet, S
    França, LR
    Le Lay, K
    Dhainaut, JF
    Vallet, B
    Launois, R
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A20 - A20
  • [46] Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?
    Friedrich, Jan O.
    Adhikari, Neill K. J.
    Meade, Maureen O.
    [J]. CRITICAL CARE, 2006, 10 (03)
  • [47] Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom
    Green, C
    Dinnes, J
    Takeda, AL
    Cuthbertson, BH
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2006, 22 (01) : 90 - 100
  • [48] Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure
    França, LR
    Launois, R
    Le Lay, K
    Aegerter, P
    Bouhassira, M
    Meshaka, P
    Guidet, B
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2006, 22 (01) : 101 - 108
  • [49] Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?
    Jan O Friedrich
    Neill KJ Adhikari
    Maureen O Meade
    [J]. Critical Care, 10
  • [50] Drotrecogin alfa (activated) treatment in severe sepsis: A 'journal club" review of the global ENHANCE trial
    Farmer, JC
    [J]. CRITICAL CARE MEDICINE, 2005, 33 (10) : 2428 - 2431
12345